手术不可行的早期肝癌患者接受经皮微波消融治疗后的长期疗效  

Efficacy analysis of percutaneous microwave ablation for patients with unresectable early stage hepatocellular carcinoma

作　　者：王能[1] 沈强[1] 许贇[1] 钱国军[1] 

机构地区：[1]第二军医大学附属东方肝胆外科医院,上海市200438

出　　处：《实用医学杂志》2016年第13期2164-2167,共4页The Journal of Practical Medicine

基　　金：国家医学重大专项(编号:2012ZX10002016)

摘　　要：目的:分析手术不可行的早期肝癌(HCC)患者接受经皮微波消融(PMVA)治疗后的长期疗效。方法:选取2007年1月至2010年1月105例手术不可行的早期肝癌患者经皮热消融治疗,观察肿瘤完全消融率、严重并发症发生率、总体生存率、无瘤生存率并分析预后相关影响因素。结果:肿瘤完全消融率95.7%,并发症发生率3.8%,1、3、5年总体生存率分别为97.1%、66.7%、46.7%,1、3、5年无瘤生存率分别为82.9%、48.6%、31.4%。年龄>65岁和肿瘤最大直径≥3 cm是影响术后无瘤生存率独立危险因素;年龄>65岁和肿瘤复发是总生存率的独立风险因素。结论 :对于手术不可行的早期HCC患者,PMWA是安全且疗效理想的治疗方法,可作为该类HCC患者的首选治疗。Objective To investigate the efficiency and prognostic factors for the patients with hepatocel- lular carcinoma （HCC） at unresectable early stage when treated with percutaneous microwave ablation. Methods From January 2007 to January 2010, 105 cases of at unresectable early stage were treated with percutaneous microwave ablation. Complete response rate, major complication rate, overall survival rates, disease-free survival rate were observed and prognostic risk factors were analyzed. Results The complete response rate was 95.7%. The major complication ratewas 3.8%. The 1-, 3-, and 5-year overall survival rates were 97.1%, 66.7%, 46.7%, and the corresponding disease-free survival rates were 82.9%, 48.6%, 31.4%, respectively. Age 〉 65 year and tumor size 〉 3 cm were independent risks for disease-free survival. Age 〉 65 year and recurrence were independent risks for overall survival. Conclusions Percutaneous microwave ablation is a safe and efficient therapy for HCC at unresectable early stage.

关 键 词：肝细胞肝癌 微波消融 疗效 

分 类 号：R735.7[医药卫生—肿瘤]